21 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Pegu A, Xu L, DeMouth ME, Fabozzi G, March K, Almasri CG, Cully MD, Wang K, Yang ES, Dias J, Fennessey CM, Hataye J, Wei RR, Rao E, Casazza JP, ... ... Asokan M, et al. Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys. Cell Reports. 38: 110199. PMID 34986348 DOI: 10.1016/j.celrep.2021.110199  0.879
2021 Dias J, Fabozzi G, March K, Asokan M, Almasri CG, Fintzi J, Promsote W, Nishimura Y, Todd JP, Lifson JD, Martin MA, Gama L, Petrovas C, Pegu A, Mascola JR, et al. Concordance of immunological events between intrarectal and intravenous SHIVAD8-EO infection when assessed by Fiebig-equivalent staging. The Journal of Clinical Investigation. 131. PMID 34623326 DOI: 10.1172/JCI151632  0.729
2021 Kwon YD, Asokan M, Gorman J, Zhang B, Liu Q, Louder MK, Lin BC, McKee K, Pegu A, Verardi R, Yang ES, Program VP, Carlton K, Doria-Rose NA, Lusso P, et al. A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention. Mabs. 13: 1946918. PMID 34328065 DOI: 10.1080/19420862.2021.1946918  0.858
2020 Kielau Kisalu N, Da Silva Pereira L, Ernste KJ, Flores-Garcia Y, Idris AH, Asokan M, Dillon M, MacDonald S, Shi W, Chen X, Pegu A, Schön A, Zavala F, Balazs AB, Francica JR, et al. Enhancing durability of CIS43 monoclonal antibody by Fc mutation or AAV delivery for malaria prevention. Jci Insight. PMID 33332286 DOI: 10.1172/jci.insight.143958  0.809
2020 Chuang GY, Asokan M, Ivleva VB, Pegu A, Yang ES, Zhang B, Chaudhuri R, Geng H, Lin BC, Louder MK, McKee K, O'Dell S, Wang H, Zhou T, Doria-Rose NA, et al. Removal of variable domain -linked glycosylation as a means to improve the homogeneity of HIV-1 broadly neutralizing antibodies. Mabs. 12: 1836719. PMID 33121334 DOI: 10.1080/19420862.2020.1836719  0.842
2020 Asokan M, Dias J, Liu C, Maximova A, Ernste K, Pegu A, McKee K, Shi W, Chen X, Almasri C, Promsote W, Ambrozak DR, Gama L, Hu J, Douek DC, et al. Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody. Proceedings of the National Academy of Sciences of the United States of America. PMID 32690707 DOI: 10.1073/Pnas.2008236117  0.855
2019 Krebs SJ, Kwon YD, Schramm CA, Law WH, Donofrio G, Zhou KH, Gift S, Dussupt V, Georgiev IS, Schätzle S, McDaniel JR, Lai YT, Sastry M, Zhang B, Jarosinski MC, ... ... Asokan M, et al. Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual. Immunity. PMID 30876875 DOI: 10.1016/J.Immuni.2019.02.008  0.808
2019 Liu Q, Lai YT, Zhang P, Louder MK, Pegu A, Rawi R, Asokan M, Chen X, Shen CH, Chuang GY, Yang ES, Miao H, Wang Y, Fauci AS, Kwong PD, et al. Improvement of antibody functionality by structure-guided paratope engraftment. Nature Communications. 10: 721. PMID 30760721 DOI: 10.1038/S41467-019-08658-4  0.879
2018 Xu K, Acharya P, Kong R, Cheng C, Chuang GY, Liu K, Louder MK, O'Dell S, Rawi R, Sastry M, Shen CH, Zhang B, Zhou T, Asokan M, Bailer RT, et al. Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. Nature Medicine. PMID 29867235 DOI: 10.1038/s41591-018-0042-6  0.825
2018 Kwon YD, Chuang GY, Zhang B, Bailer RT, Doria-Rose NA, Gindin TS, Lin B, Louder MK, McKee K, O'Dell S, Pegu A, Schmidt SD, Asokan M, Chen X, Choe M, et al. Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody. Cell Reports. 22: 1798-1809. PMID 29444432 DOI: 10.1016/J.Celrep.2018.01.023  0.829
2018 Xu K, Acharya P, Kong R, Cheng C, Chuang GY, Liu K, Louder MK, O'Dell S, Rawi R, Sastry M, Shen CH, Zhang B, Zhou T, Asokan M, Bailer RT, et al. Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. Nature Medicine. 24: 857-867. DOI: 10.2210/Pdb6Cdp/Pdb  0.876
2017 Xu L, Pegu A, Rao E, Doria-Rose N, Beninga J, McKee K, Lord DM, Wei RR, Deng G, Louder M, Schmidt SD, Mankoff Z, Wu L, Asokan M, Beil C, et al. Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. Science (New York, N.Y.). PMID 28931639 DOI: 10.1126/Science.Aan8630  0.864
2016 Huang J, Kang BH, Ishida E, Zhou T, Griesman T, Sheng Z, Wu F, Doria-Rose NA, Zhang B, McKee K, O'Dell S, Chuang GY, Druz A, Georgiev IS, Schramm CA, ... ... Asokan M, et al. Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth. Immunity. 45: 1108-1121. PMID 27851912 DOI: 10.1016/J.Immuni.2016.10.027  0.85
2016 Joyce MG, Wheatley AK, Thomas PV, Chuang GY, Soto C, Bailer RT, Druz A, Georgiev IS, Gillespie RA, Kanekiyo M, Kong WP, Leung K, Narpala SN, Prabhakaran MS, Yang ES, ... ... Asokan M, et al. Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses. Cell. PMID 27453470 DOI: 10.1016/J.Cell.2016.06.043  0.763
2016 Kwon YD, Georgiev IS, Ofek G, Zhang B, Asokan M, Bailer RT, Bao A, Caruso W, Chen X, Choe M, Druz A, Ko SY, Louder MK, McKee K, O'Dell S, et al. Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design. Journal of Virology. PMID 27053554 DOI: 10.1128/Jvi.03246-15  0.809
2015 Pegu A, Asokan M, Wu L, Wang K, Hataye J, Casazza JP, Guo X, Shi W, Georgiev I, Zhou T, Chen X, O'Dell S, Todd JP, Kwong PD, Rao SS, et al. Activation and lysis of human CD4 cells latently infected with HIV-1. Nature Communications. 6: 8447. PMID 26485194 DOI: 10.1038/Ncomms9447  0.807
2015 Doria-Rose NA, Bhiman JN, Roark RS, Schramm CA, Gorman J, Chuang GY, Pancera M, Cale EM, Ernandes MJ, Louder MK, Asokan M, Bailer RT, Druz A, Fraschilla IR, Garrett NJ, et al. A new member of the V1V2-directed CAP256-VRC26 lineage that shows increased breadth and exceptional potency. Journal of Virology. PMID 26468542 DOI: 10.1128/Jvi.01791-15  0.792
2015 Asokan M, Rudicell RS, Louder M, McKee K, O'Dell S, Stewart-Jones G, Wang K, Xu L, Chen X, Choe M, Chuang G, Georgiev IS, Joyce MG, Kirys T, Ko S, et al. Bispecific antibodies targeting different epitopes on the HIV-1 envelope exhibit broad and potent neutralization. Journal of Virology. PMID 26446600 DOI: 10.1128/Jvi.02097-15  0.876
2014 Asokan M, Sachidanandam V, Satish KS, Ranga U. Attenuation of immune activation in an open-label clinical trial for HIV-AIDS using a polyherbal formulation. Virusdisease. 25: 302-13. PMID 25674597 DOI: 10.1007/s13337-014-0218-8  0.821
2013 Asokan M, Lone IN, Mukthey AB, Siddhartha P, Mariappa G, Kotehal PK, Satish B, Wilson E, Sahayam S, Velayutham G, Perumal R, Baskaran K, Rengarajan D, Muthusamy R, Philip M, et al. Evident stabilization of the clinical profile in HIV/AIDS as evaluated in an open label clinical trial using a polyherbal formulation. The Indian Journal of Medical Research. 137: 1128-44. PMID 23852294  0.83
2012 Bachu M, Yalla S, Asokan M, Verma A, Neogi U, Sharma S, Murali RV, Mukthey AB, Bhatt R, Chatterjee S, Rajan RE, Cheedarla N, Yadavalli VS, Mahadevan A, Shankar SK, et al. Multiple NF-κB sites in HIV-1 subtype C long terminal repeat confer superior magnitude of transcription and thereby the enhanced viral predominance. The Journal of Biological Chemistry. 287: 44714-35. PMID 23132857 DOI: 10.1074/Jbc.M112.397158  0.755
Show low-probability matches.